Sparks commentary - Cantargia

Healthcare

Sparks - Cantargia

More on this equity
Cantargia (OMX: CANTA) reports positive CAN10 update
Published by Arron Aatkar, PhD

Cantargia has reported encouraging pharmacokinetic data from the first cohort in the multiple ascending dose portion of the CAN10 study. Importantly, the data align with the single dose portion of the programme and further support continuation at four-weekly dosing. Additionally, the FDA has provided positive feedback on Cantargia’s plans for the design of a Phase II trial in hidradenitis suppurativa (often referred to as HS). This decision has been backed by a scientific advisory board comprising key opinion leaders in the field. Preparations for Phase II are ongoing, and management expects to submit an investigational new drug application in H225.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.